Neurodegenerative brain disease and trauma affect over 35 million patients worldwide, accounting for over $1.3 trillion of nondiscretionary healthcare spending every year.
Unfortunately, failed drug trials, ineffective treatments, and delayed diagnoses limit therapeutic options. The lack of blood testing products as tools for breakthrough discoveries in drug R&D, limiting pipeline advancement is a significant gap that ZelosDx addresses with our patented technology.
Our proprietary biomarker technology will be used by pharmaceutical companies as drug discovery tools and by research professionals conducting brain disease studies.
We seek research collaborators to license and adapt our proprietary technology for blood testing kits and automated laboratory equipment, and pharmaceutical collaborators seeking biomarker technology for drug discovery tools to be used as endpoints in their clinical trials in these neurodegenerative markets. The company is looking to make the right partnering or licensing connection!
Copyright © 2021 ZelosDx - All Rights Reserved.